Keywords: Cannabis, Hepatic disorders, Gastroenterological disorders, Position statement Authors: Christopher N Andrews, Shane M Devlin, Bernard Le Foll, Benedikt Fischer,…
Abstract Objective: Forthcoming legislative changes will legalize and make cannabis widely available in Canada. We conducted an analysis of Ontario’s…
Abstract BACKGROUND: The therapeutic effects of cannabinoid compounds have been the center of many investigations. This study provides a synthesis…
Abstract Cannabis sativa is a medicinal herb with a diverse range of chemotypes that can exert both anxiolytic and anxiogenic…
Abstract Neurological therapeutics have been hampered by its inability to advance beyond symptomatic treatment of neurodegenerative disorders into the realm…
Abstract Objective: Cannabidiol (CBD), one of the non-psychotomimetic compounds of Cannabis sativa, causes anxiolytic-like effects in animals, with typical bell-shaped…
Abstract Background: Medical cannabis has been available in the State of Minnesota since July 2015 through the Minnesota Medical Cannabis…
Abstract Because of its inherent qualities, in-tube solid-phase microextraction (IT-SPME) coupled on-line to nanoliquid chromatography (nanoLC) can be a very…
Abstract Cannabinoids can cross the placenta, thus may interfere with fetal endocannabinoid signaling during neurodevelopment, causing long-lasting deficits. Despite increasing…
Abstract Background: Changes in cannabis regulation globally make it increasingly important to determine what predicts an individual’s risk of experiencing…